Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?

Current Cardiovascular Risk Reports

Volumn 3, Issue 2, 2009, Pages 137-143

  Arsenault, Benoit J ^b   Stroes, Erik S G ^b   Boekholdt, S Matthijs ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952241851     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-009-0022-y     Document Type: Article

References (49)

1. Navab M, Ananthramaiah GM, Reddy ST, et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45: 993-1007.
2. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25: 29-38.
3. Tsimikas S: In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008, 101: 34D-42D.
4. Genest J: The Yin and Yang of high-density lipoprotein cholesterol. J Am Coll Cardiol 2008, 51: 643-644.
5. Maki-Petaja KM, Cheriyan J, Booth AD, et al.: Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol 2008 Jun 18 (Epub ahead of print).
6. Heinecke JW: The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007, 9: 249-251.
7. Mohiuddin I, Chai H, Lin PH, et al.: Nitrotyrosine and chlorotyrosine: clinical significance and biological functions in the vascular system. J Surg Res 2006, 133: 143-149.
8. Link JJ, Rohatgi A, de Lemos JA: HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 2007, 32: 268-314.
9. Joyce CW, Amar MJ, Lambert G, et al.: The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A 2002, 99: 407-412.
10. Sirtori CR, Calabresi L, Franceschini G, et al.: Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001, 103: 1949-1954.
11. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290: 2292-2300.
12. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL-guardian angel of the arterial wall?Nat Clin Pract Cardiovasc Med 2006, 3: 144-153.
13. van der Poll T, Braxton CC, Coyle SM, et al.: Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995, 63: 3396-3400.
14. Zhang B, Bai H, Liu R, et al.: Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men. Metabolism 2004, 53: 423-429.
15. Perségol L, Verges B, Gambert P, et al.: Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res 2007, 48: 1396-1401.
16. Perségol L, Foissac M, Lagrost L, et al.: HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007, 50: 2384-2387.
17. Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101: 13032-13037.
18. Zheng L, Nukuna B, Brennan ML, et al.: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114: 529-541.
19. Pennathur S, Bergt C, Shao B, et al.: Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004, 279: 42977-42983.
20. Marsche G, Hammer A, Oskolkova O, et al.: Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 2002, 277: 32172-32179.
21. Daugherty A, Dunn JL, Rateri DL, et al.: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94: 437-444.
22. Sugiyama S, Okada Y, Sukhova GK, et al.: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158: 879-891.
23. Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99: 2075-2081.
24. Morton LW, Puddey IB, Croft KD: Comparison of nitration and oxidation of tyrosine in advanced human carotid plaque proteins. Biochem J 2003, 370: 339-344.
25. Wang Z, Nicholls SJ, Rodriguez ER, et al.: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13: 1176-1184.
26. Hazen SL, Zhang R, Shen Z, et al.: Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999, 85: 950-958.
27. Kumar AP, Reynolds WF: Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005, 331: 442-451.
28. Zhou T, Zhou SH, Qi SS, et al.: The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006, 368: 168-172.
29. Shishehbor MH, Aviles RJ, Brennan ML, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289: 1675-1680.
30. Davey Smith G, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?Int J Epidemiol 2003, 32: 1-22.
31. Piedrafita FJ, Molander RB, Vansant G, et al.: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996, 271: 14412-14420.
32. Nikpoor B, Turecki G, Fournier C, et al.: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001, 142: 336-339.
33. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al.: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int 2003: S172-S176.
34. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, et al.: Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004, 116: 429-430.
35. Makela R, Loimaala A, Nenonen A, et al.: The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin Biochem 2008, 41: 532-537.
36. Kutter D, Devaquet P, Vanderstocken G, et al.: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?Acta Haematol 2000, 104: 10-15.
37. Zhang R, Brennan ML, Fu X, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286: 2136-2142.
38. Kubala L, Lu G, Baldus S, et al.: Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008, 394: 59-62.
39. Vita JA, Brennan ML, Gokce N, et al.: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004, 110: 1134-1139.
40. Exner M, Minar E, Mlekusch W, et al.: Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006, 47: 2212-2218.
41. Ndrepepa G, Braun S, Mehilli J, et al.: Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008, 38: 90-96.
42. Meuwese MC, Trip MD, van Wissen S, et al.: Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 2008, 197: 916-921.
43. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50: 159-165.
44. Brennan ML, Penn MS, van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349: 1595-1604.
45. Cavusoglu E, Ruwende C, Eng C, et al.: Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007, 99: 1364-1368.
46. Stefanescu A, Braun S, Ndrepepa G, et al.: Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008, 155: 356-360.
47. Mocatta TJ, Pilbrow AP, Cameron VA, et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007, 49: 1993-2000.
48. Baldus S, Heeschen C, Meinertz T, et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108: 1440-1445.
49. Khan SQ, Kelly D, Quinn P, et al.: Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007, 93: 826-831.